UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001537
Receipt number R000001844
Scientific Title Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer
Date of disclosure of the study information 2008/12/01
Last modified on 2016/04/27 13:55:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer

Acronym

Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer

Scientific Title

Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer

Scientific Title:Acronym

Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

1. To evaluate the biochemical progression-free survival of patients with locally advanced prostate cancer treated by high dose rate brachytherapy and external beam radiotherapy combined with long-term (40 months) hormonal therapy in comparison with short-term (4 months) hormonal therapy.
2. Surrogate end points of this clinical trial are overall survival, cause specific survival and clinical progression-free survival, QOL and safety.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

Biochemical progression-free survival (PFS)

Key secondary outcomes

Overall survival
Cause- specific survival
Clinical progression-free survival
QOL
Safety


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

NO

Dynamic allocation

YES

Institution consideration


Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

Patients receive neoadjuvant hormonal therapy for three months and undergo high dose rate brachytherapy and external radiation therapy with concurrent hormonal therapy. Patients then receive adjuvant hormonal therapy for up to 36 months.

Interventions/Control_2

Patients receive neoadjuvant hormonal therapy for three months and undergo high dose rate brachytherapy and external radiation therapy with concurrent hormonal therapy. Patients are followed up without adjuvant hormonal therapy.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male

Key inclusion criteria

1. Histologically confirmed adenocarcinoma of the prostate
2. Previously untreated disease
3. Prostate-Specific Antigen (PSA) 20.1-100 ng/mL
4. T2N0M0(Gleason score >or= 8) or T3N0M0(Any Gleason score)
5. Rate of positive core of prostate biopsy >or= 50%
6. ECOG performance status 0-1
7. Age <or= 80

Key exclusion criteria

1. Patients with other cancer requiring treatment
2. Patients with serious complications
3. Patients who fall under the following(Leukocyte count < 3,000/uL, Hemoglobin < 10.0g/dL, Platelet count < 75,000/uL, AST, ALT and ALP > 2.5 times upper limit of normal (ULN), Serum Creatinine > 1.5 times ULN)

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Isao Hara

Organization

Wakayama Medical University

Division name

Department of Urology

Zip code


Address

811-1, Kimiidera, Wakayama City, Wakayama, 641-8590, Japan

TEL

073-441-0637

Email

hara@wakayama-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Isco Hara, M.D.

Organization

Wakayama Medical University

Division name

Department of Urology

Zip code


Address

811-1, Kimiidera, Wakayama City, Wakayama, 641-8590, Japan

TEL

073-441-0637

Homepage URL


Email

hara@wakayama-med.ac.jp


Sponsor or person

Institute

Wakayama Medical University, Department of Urology

Institute

Department

Personal name



Funding Source

Organization

Department of Urology
Wakayama Medical University

Organization

Division

Category of Funding Organization

Local Government

Nationality of Funding Organization



Other related organizations

Co-sponsor

None

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2008 Year 09 Month 16 Day

Date of IRB


Anticipated trial start date

2008 Year 11 Month 01 Day

Last follow-up date

2020 Year 09 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 12 Month 01 Day

Last modified on

2016 Year 04 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001844


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name